title: Single-antibiotic use for penetrating abdominal trauma.
abstract: A prospective randomized study compared the use of moxalactam disodium vs clindamycin phosphate and tobramycin sulfate for treatment of 190 patients with penetrating abdominal trauma. Twenty-seven patients were disqualified because of early death or failure to follow the protocol. The patients in each group were comparable regarding the cause and severity of injury. No significant difference was seen in the incidence of intra-abdominal infection between the moxalactam-treated group (13%) and the clindamycin- and tobramycin-treated group (9%). The intra-abdominal infection rate in patients with colon injuries (21%) was significantly increased when compared with the patients without colon injuries (6%), but the antibiotic regimen did not significantly change the infection rate. No evidence of bleeding problems from moxalactam were noted. Changes in prothrombin and partial thromboplastin times appeared to be related to shock rather than the use of moxalactam. The most severe coagulopathies occurred prior to moxalactam therapy and were seen only in those patients who had shock requiring 10 or more units of blood. Moxalactam is as effective as combination (clindamycin and tobramycin) antimicrobial therapy in patients with penetrating abdominal trauma.
mesh_terms: D000007:Abdominal Injuries / Q000097:blood / Q000150:complications / Q000601:surgery*; D001777:Blood Coagulation / Q000187:drug effects; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use; D003106:Colon / Q000293:injuries; D004359:Drug Therapy, Combination; D006801:Humans; D009070:Moxalactam / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011182:Postoperative Care; D011292:Premedication; D011446:Prospective Studies; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use; D014946:Wound Infection / Q000517:prevention & control*; D014950:Wounds, Penetrating / Q000097:blood / Q000150:complications / Q000601:surgery*
chemical_list: D002981:Clindamycin; D009070:Moxalactam; D014031:Tobramycin